Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts.

MG Klug, MH Soonpaa, GY Koh… - The Journal of clinical …, 1996 - Am Soc Clin Investig
MG Klug, MH Soonpaa, GY Koh, LJ Field
The Journal of clinical investigation, 1996Am Soc Clin Investig
This study describes a simple approach to generate relatively pure cultures of
cardiomyocytes from differentiating murine embryonic stem (ES) cells. A fusion gene
consisting of the alpha-cardiac myosin heavy chain promoter and a cDNA encoding
aminoglycoside phosphotransferase was stably transfected into pluripotent ES cells. The
resulting cell lines were differentiated in vitro and subjected to G418 selection.
Immunocytological and ultrastructural analyses demonstrated that the selected …
This study describes a simple approach to generate relatively pure cultures of cardiomyocytes from differentiating murine embryonic stem (ES) cells. A fusion gene consisting of the alpha-cardiac myosin heavy chain promoter and a cDNA encoding aminoglycoside phosphotransferase was stably transfected into pluripotent ES cells. The resulting cell lines were differentiated in vitro and subjected to G418 selection. Immunocytological and ultrastructural analyses demonstrated that the selected cardiomyocyte cultures (> 99% pure) were highly differentiated. G418 selected cardiomyocytes were tested for their ability to form grafts in the hearts of adult dystrophic mice. The fate of the engrafted cells was monitored by antidystrophin immunohistology, as well as by PCR analysis with primers specific for the myosin heavy chain-aminoglycoside phosphotransferase transgene. Both analyses revealed the presence of ES-derived cardiomyocyte grafts for as long as 7 wk after implantation, the latest time point analyzed. These studies indicate that a simple genetic manipulation can be used to select essentially pure cultures of cardiomyocytes from differentiating ES cells. Moreover, the resulting cardiomyocytes are suitable for the formation of intracardiac grafts. This selection approach should be applicable to all ES-derived cell lineages.
The Journal of Clinical Investigation